• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Beilstein Journal of Nanotechnology >Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): Technical description experimental validation and first proof of concept
【2h】

Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): Technical description experimental validation and first proof of concept

机译：高温腔内纳米气雾疗法（HINAT）作为加压腹膜内气雾化学疗法（PIPAC）的改良方法：技术说明实验验证和初步概念验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Background: The delivery of aerosolised chemotherapeutic substances into pressurised capnoperitonea has been reported to be more effective than conventional liquid chemotherapy for the treatment of peritoneal carcinomatosis. However, recent reports reveal limitations of the currently available technology. >Material and Methods: A novel approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC), called hyperthermic intracavitary nanoaerosol therapy (HINAT), based on extracavitary generation of hyperthermic and unipolar charged aerosols, was developed. The aerosol size distribution, the spatial drug distribution and in-tissue depth penetration of HINAT were studied by laser diffraction spectrometry, differential electrical mobility analysis, time of flight spectrometry, scintigraphic peritoneography and fluorescence microscopy. All experiments were performed contemporaneous with conventional PIPAC for the purpose of comparison. Furthermore, a first proof of concept was simulated in anesthetised German Landrace pigs. >Results: HINAT provides a nanometre-sized (63 nm) unipolar-charged hyperthermic (41 °C) drug aerosol for quasi uniform drug deposition over the whole peritoneum with significantly deeper drug penetration than that offered by conventional PIPAC.
机译：>背景：据报道，将雾化的化学治疗物质输送到加压的气胸手术中比常规液体化学疗法更有效地治疗腹膜癌。但是，最近的报道揭示了当前可用技术的局限性。 >材料和方法：基于腔内生成高温和单极带电气雾剂，开发了一种新颖的加压腹腔内气雾化学疗法（PIPAC）方法，称为高温腔内纳米气雾剂疗法（HINAT）。通过激光衍射光谱，差动电迁移率分析，飞行时间光谱，闪烁体腹膜造影和荧光显微镜研究了HINAT的气溶胶粒径分布，空间药物分布和组织内穿透深度。为了进行比较，所有实验均与常规PIPAC同时进行。此外，在麻醉的德国长白猪中模拟了第一个概念验证。 >结果： HINAT提供了纳米级（63 nm）的单极性带电（41°C）药物气雾剂，可在整个腹膜上实现均匀的药物沉积，并且比常规PIPAC所提供的药物渗透深度更深。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号